NO20083868L - IAP BIR domenebindende forbindelser - Google Patents

IAP BIR domenebindende forbindelser

Info

Publication number
NO20083868L
NO20083868L NO20083868A NO20083868A NO20083868L NO 20083868 L NO20083868 L NO 20083868L NO 20083868 A NO20083868 A NO 20083868A NO 20083868 A NO20083868 A NO 20083868A NO 20083868 L NO20083868 L NO 20083868L
Authority
NO
Norway
Prior art keywords
iap
bes
domain
binding connections
connections
Prior art date
Application number
NO20083868A
Other languages
English (en)
Norwegian (no)
Inventor
Alain Boudreault
Patrick Bureau
James Jaquith
John W Gillard
Original Assignee
Aegera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegera Therapeutics Inc filed Critical Aegera Therapeutics Inc
Publication of NO20083868L publication Critical patent/NO20083868L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20083868A 2006-03-16 2008-09-09 IAP BIR domenebindende forbindelser NO20083868L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78252306P 2006-03-16 2006-03-16
US87699406P 2006-12-26 2006-12-26
PCT/CA2007/000428 WO2007104162A1 (en) 2006-03-16 2007-03-16 Iap bir domain binding compounds

Publications (1)

Publication Number Publication Date
NO20083868L true NO20083868L (no) 2008-11-06

Family

ID=38509005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083868A NO20083868L (no) 2006-03-16 2008-09-09 IAP BIR domenebindende forbindelser

Country Status (15)

Country Link
US (5) US7579320B2 (US08039623-20111018-C00020.png)
EP (1) EP2004600A4 (US08039623-20111018-C00020.png)
JP (1) JP5419468B2 (US08039623-20111018-C00020.png)
KR (1) KR101446907B1 (US08039623-20111018-C00020.png)
AU (1) AU2007224932B2 (US08039623-20111018-C00020.png)
BR (1) BRPI0709610A2 (US08039623-20111018-C00020.png)
CA (1) CA2581960C (US08039623-20111018-C00020.png)
IL (1) IL193951A (US08039623-20111018-C00020.png)
MX (1) MX2008011837A (US08039623-20111018-C00020.png)
NO (1) NO20083868L (US08039623-20111018-C00020.png)
NZ (1) NZ571577A (US08039623-20111018-C00020.png)
PH (1) PH12014502420A1 (US08039623-20111018-C00020.png)
SG (1) SG170739A1 (US08039623-20111018-C00020.png)
TW (2) TWI504597B (US08039623-20111018-C00020.png)
WO (1) WO2007104162A1 (US08039623-20111018-C00020.png)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020060A2 (en) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
AU2006216450C1 (en) * 2005-02-25 2013-01-10 Medivir Ab Dimeric IAP inhibitors
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
EP1973899A4 (en) 2005-12-19 2010-10-20 Genentech Inc HEMMER OF IAP
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
JP2009530424A (ja) * 2006-03-21 2009-08-27 ジョイアント ファーマスーティカルズ、インク． 小分子アポトーシスプロモーター
MY159563A (en) 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
CL2007002167A1 (es) * 2006-07-24 2009-01-23 Tetralogic Pharm Corp Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
AU2008240153B2 (en) * 2007-04-12 2013-01-31 Joyant Pharmaceuticals, Inc. SMAC mimetic dimers and trimers useful as anti-cancer agents
WO2008134679A1 (en) * 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
US20110008802A1 (en) * 2007-05-07 2011-01-13 Tetralogic Pharmaceuticals Corp. TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS
US20100203012A1 (en) * 2007-05-30 2010-08-12 Aegera Therapeutics, Inc. Iap bir domain binding compounds
NZ588652A (en) 2008-04-23 2012-09-28 Rigel Pharmaceuticals Inc Carboxamide compounds for the treatment of metabolic disorders
US20110117081A1 (en) * 2008-05-05 2011-05-19 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
CA2728933A1 (en) * 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
AU2009279924B2 (en) * 2008-08-02 2014-10-02 Genentech, Inc. Inhibitors of IAP
WO2010015090A1 (en) * 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US20110177060A1 (en) * 2008-09-19 2011-07-21 Aegera Therapeutics, Inc. Iap bir domain binding compounds
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US8551955B2 (en) * 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics
KR20120140658A (ko) 2010-02-12 2012-12-31 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
CA2916970A1 (en) * 2016-01-08 2017-07-08 Pharmascience Inc. A smac mimetic compound for use in the treatment of proliferative diseases
CN110944719A (zh) * 2017-07-25 2020-03-31 合帕吉恩治疗公司 凋亡蛋白的二聚肽抑制剂
CN117130035A (zh) * 2017-08-18 2023-11-28 南京中硼联康医疗科技有限公司 生物剂量计及具有其的中子捕获治疗系统
WO2019180627A1 (en) * 2018-03-21 2019-09-26 Piramal Enterprises Limited AN IMPROVED ASYMMETRIC SYNTHESIS OF alpha-(DIARYLMETHYL) ALKYL AMINES
CN112533898A (zh) 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 杂环化合物
EP3886909A4 (en) * 2018-11-29 2023-03-29 Comera Life Sciences, Inc. ADDITOR COMPOUNDS FOR PROTEIN PROCESSING
KR20220012844A (ko) * 2019-04-05 2022-02-04 헤파진 테라퓨틱스 (에이치케이) 리미티드 아포토시스 단백질 억제제의 2가 길항제
WO2020223403A1 (en) * 2019-04-29 2020-11-05 The Regents Of The University Of California Anticancer smac derivatives
JPWO2021020585A1 (US08039623-20111018-C00020.png) 2019-07-31 2021-02-04
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2022198196A1 (en) 2021-03-15 2022-09-22 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
WO2023127331A1 (ja) * 2021-12-27 2023-07-06 株式会社トクヤマ ペプチド製造方法、保護基の除去方法、除去剤、及びベンジル化合物
JP7260725B1 (ja) * 2021-12-27 2023-04-18 株式会社トクヤマ ペプチド製造方法、保護基の除去方法、及び除去剤

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US89896A (en) * 1869-05-11 Improvement in bee-hive
US211627A (en) * 1879-01-28 Improvement in perforating-stamps
US93428A (en) * 1869-08-10 Improvement in spurs for excelsior-machines
US219140A (en) * 1879-09-02 Improvement in the art of ornamenting metallic foils
US194741A (en) * 1877-08-28 Improvement in circular looms
US25347A (en) * 1859-09-06 Improvement
US207525A (en) * 1878-08-27 Improvement in car-coupling draw-bars
US180828A (en) * 1876-08-08 Improvement in horse-powers
US69812A (en) * 1867-10-15 Improved refrigerator
US93429A (en) * 1869-08-10 Improvement in flasks for vulcanizing rubber plates for setting teeth
US32437A (en) * 1861-05-28 Improvement in steam-plows
US258581A (en) * 1882-05-30 husset
JPH0680077B2 (ja) 1985-02-08 1994-10-12 サントリー株式会社 プロリンエンドペプチダ−ゼインヒビタ−活性を有する新規ペプチド化合物
JPH04208299A (ja) 1990-11-30 1992-07-29 Ajinomoto Co Inc プロリルエンドペプチターゼ阻害ペプチド
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AUPN727595A0 (en) * 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic compositions
JP4208299B2 (ja) 1998-08-19 2009-01-14 東レ株式会社 金属板貼合わせ成形加工用ポリエステルフィルム
US6110691A (en) * 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002026775A2 (en) 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
JP2004536079A (ja) * 2001-05-16 2004-12-02 アンテックスファーマ・インコーポレーテッド 置換１−ベンズアゼピンおよびその誘導体
MXPA03010762A (es) 2001-05-31 2005-03-07 Univ Princeton Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap.
AU2002314165B2 (en) * 2001-06-19 2008-02-21 Altana Pharma Ag Tryptase inhibitors
US20060258581A1 (en) 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
US20060128632A1 (en) * 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
DE60324964D1 (de) 2002-07-15 2009-01-08 Univ Princeton Iap-bindende verbindungen
FR2844271A1 (fr) * 2002-09-09 2004-03-12 Oreal Derives bis-paraphenylenediamine a groupement pyrrolidinyle et utilisation de ces derives pour la coloration de fibres keratiniques
WO2004050895A2 (en) * 2002-11-27 2004-06-17 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
US20040180828A1 (en) 2003-01-30 2004-09-16 Yigong Shi Caspase-9 : BIR domain of XIAP complexes and methods of use
AU2004291936A1 (en) * 2003-11-13 2005-06-02 Burnham Institute Compositions and methods for screening pro-apoptotic compounds
CN1933847A (zh) 2004-01-16 2007-03-21 密歇根大学董事会 Smac肽模拟物及其应用
KR20060126548A (ko) 2004-02-05 2006-12-07 노파르티스 아게 (ａ) ＤＮＡ 토포이소머라제 억제제 및 (ｂ) ＩＡＰ 억제제조합물
JP4674231B2 (ja) * 2004-03-01 2011-04-20 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ２量体小分子アポトーシス増強剤
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
CA2560162C (en) 2004-04-07 2013-05-21 Novartis Ag Inhibitors of iap
US7244851B2 (en) * 2004-07-02 2007-07-17 Genentech, Inc. Inhibitors of IAP
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
CA2573644A1 (en) 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
WO2006020060A2 (en) * 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
AU2006216450C1 (en) * 2005-02-25 2013-01-10 Medivir Ab Dimeric IAP inhibitors
US20070003535A1 (en) 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
DE102005017116A1 (de) 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
EP1888619B1 (en) 2005-05-25 2013-04-17 2cureX ApS Compounds modifying apoptosis
BRPI0611922A2 (pt) 2005-06-08 2010-10-05 Novartis Ag compostos orgánicos
CA2617642A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
EP1973899A4 (en) 2005-12-19 2010-10-20 Genentech Inc HEMMER OF IAP
CA2632256A1 (en) 2005-12-20 2007-07-05 Novartis Ag Combination of an iap-inhibitor and a taxane7
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
JP2009530424A (ja) 2006-03-21 2009-08-27 ジョイアント ファーマスーティカルズ、インク． 小分子アポトーシスプロモーター
JP5230610B2 (ja) 2006-05-05 2013-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 二価ｓｍａｃ模倣物およびその使用
MY159563A (en) 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
US20100113326A1 (en) 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100143499A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CL2007002167A1 (es) 2006-07-24 2009-01-23 Tetralogic Pharm Corp Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
US20100144650A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20080951A1 (es) 2006-08-02 2008-09-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
BRPI0719221A2 (pt) 2006-10-12 2014-03-18 Novartis Ag Derivados de pirrolidina como inibidores de iap
JP2010507096A (ja) 2006-10-19 2010-03-04 ノバルティス アーゲー 有機化合物
WO2008067280A2 (en) 2006-11-28 2008-06-05 Novartis Ag Combination of iap inhibitors and flt3 inhibitors
WO2008085610A1 (en) 2006-11-28 2008-07-17 Novartis Ag Use of iap inhibitors for the treatment of acute myeloid leukemia
CA2670728A1 (en) 2006-12-07 2008-06-19 Novartis Ag Pyridine derivatives used as xiap inhibitors
KR20090094461A (ko) 2006-12-19 2009-09-07 제넨테크, 인크. Ｉａｐ의 이미다조피리딘 억제제
AU2008240153B2 (en) 2007-04-12 2013-01-31 Joyant Pharmaceuticals, Inc. SMAC mimetic dimers and trimers useful as anti-cancer agents
PL2139490T3 (pl) 2007-04-13 2014-11-28 Univ Michigan Regents Diazobicykliczne mimetyki Smac i ich zastosowania
WO2008134679A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
US20100203012A1 (en) 2007-05-30 2010-08-12 Aegera Therapeutics, Inc. Iap bir domain binding compounds
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers

Also Published As

Publication number Publication date
JP5419468B2 (ja) 2014-02-19
US20100221261A1 (en) 2010-09-02
EP2004600A1 (en) 2008-12-24
TW201538520A (zh) 2015-10-16
JP2009529544A (ja) 2009-08-20
TWI504597B (zh) 2015-10-21
BRPI0709610A2 (pt) 2011-07-19
CA2581960A1 (en) 2007-09-16
KR20080112304A (ko) 2008-12-24
TWI543988B (zh) 2016-08-01
PH12014502420B1 (en) 2015-11-16
IL193951A (en) 2015-09-24
RU2008140935A (ru) 2010-04-27
US20080069812A1 (en) 2008-03-20
NZ571577A (en) 2011-09-30
SG170739A1 (en) 2011-05-30
PH12014502420A1 (en) 2015-11-16
US7645741B2 (en) 2010-01-12
US9365614B2 (en) 2016-06-14
US8765681B2 (en) 2014-07-01
AU2007224932B2 (en) 2013-05-23
US20140336134A1 (en) 2014-11-13
CA2581960C (en) 2015-11-24
KR101446907B1 (ko) 2014-10-06
MX2008011837A (es) 2009-02-10
US20080207525A1 (en) 2008-08-28
US7579320B2 (en) 2009-08-25
AU2007224932A1 (en) 2007-09-20
WO2007104162A1 (en) 2007-09-20
EP2004600A4 (en) 2012-05-02
US20130071411A1 (en) 2013-03-21
TW200800961A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
NO20083868L (no) IAP BIR domenebindende forbindelser
SMT201300085B (it) Composti di pirrolo
WO2008108380A3 (en) Pyrrole compounds
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
TW200833675A (en) Nicotinamide derivatives
NO20082338L (no) Pyrimidinderivater for behandling av avvikende cellevekst
WO2008057775A3 (en) Heterocyclic amide compounds useful as kinase inhibitors
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
EA201171000A1 (ru) Производные азаспиранилалкилкарбаматов в форме 5-членных гетероциклов, способ их получения и применение в терапии
EA200700758A1 (ru) Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
TW200710084A (en) Process for the synthesis of organic compounds
WO2007081690A3 (en) Inhibitors of protein kinases
DK1745010T3 (da) Substituerede cyklohexyl-1,4-diaminderivater
ATE488510T1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
EA200801123A1 (ru) Производные 6-гетероарилпиридоиндолона, способ их получения и применение их в терапии
MY137964A (en) Benzofuran derivative
EA201001252A1 (ru) Способ получения производных 3,6-дигидро-1,3,5-триазина
NO20062307L (no) Spirofuropyridinarylderivater
DE60108089D1 (de) Heterozyclische oder benzol derivate von liponsäure, deren herstellung und deren verwendung als heilmittel
EA200401432A1 (ru) Сложноэфирные производные декагидроизохинолин-3-карбоновой кислоты в качестве анальгетиков
EA200601248A1 (ru) Новые многократно замещённые соединения 1,1-пиридилоксициклопропанамина, способ их получения и фармацевтические композиции, которые их содержат
NO20064410L (no) Fremgangsmate for fremstilling av tryptaseinhibitorer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: PHARMASCIENCE INC, CA

FC2A Withdrawal, rejection or dismissal of laid open patent application